Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.
Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–48.
Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–19.
Hillengass J, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28(9):1606–10.
Vij R, Fowler KJ, Shokeen M. New approaches to molecular imaging of multiple myeloma. J Nucl Med. 2016;57(1):1–4.
Barlogie B, et al. Treatment of multiple myeloma. Blood. 2004;103(1):20–32.
Barlogie B, et al. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043–51.
Martinez-Lopez J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–34.
Fulciniti M, Munshi NC, Martinez-Lopez J. Deep response in multiple myeloma: a critical review. Biomed Res Int. 2015;2015:832049.
Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
Rasche L, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713–22.
Fiordelisi MF, et al. Preclinical molecular imaging for precision medicine in breast cancer mouse models. Contrast Media Mol Imaging. 2019;2019:8946729.
Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007;48(6):18N-21N.
Barwick T, et al. Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol. 2019;92(1095):20180768.
Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5):545–80.
Incoronato M, et al. Radiogenomic analysis of oncological data: a technical survey. Int J Mol Sci. 2017;18(4):805.
Cai W, et al. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006;5(11):2624–33.
Pan D, et al. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol. 2009;70(2):274–85.
Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Juweid ME, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.
Kazama T, et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005;25(1):191–207.
Sundaram S, et al. FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials. Am J Nucl Med Mol Imaging. 2018;8(6):421–7.
Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A. Positron emission tomography (PET) radiopharmaceuticals in multiple myeloma. Molecules. 2019;25(1):134.
Ehlerding EB, et al. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487–92.
Ghai A, et al. Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. Eur J Nucl Med Mol Imaging. 2021;48(5):1302–11.
Rasche L, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30–4.
Ulaner GA, et al. (18)F-FDG PET/CT for systemic staging of newly diagnosed breast cancer in men. J Nucl Med. 2019;60(4):472–7.
Lapa C, et al. [(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma—comparison to [(18)F]FDG and laboratory values. Theranostics. 2017;7(1):205–12.
Sikkandhar MG, et al. Theranostic probes for targeting tumor microenvironment: an overview. Int J Mol Sci. 2017;18(5):1036.
Soodgupta D, et al. Very late antigen-4 (alpha(4)beta(1) Integrin) targeted PET imaging of multiple myeloma. PLoS ONE. 2013;8(2):e55841.
Holzmann B, Gosslar U, Bittner M. Alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol. 1998;231:125–41.
Matsunaga T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9(9):1158–65.
Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38(1–2):71–81.
Soodgupta D, et al. Ex vivo and in vivo evaluation of overexpressed VLA-4 in multiple myeloma using LLP2A imaging agents. J Nucl Med. 2016;57(4):640–5.
Beaino W, Anderson CJ. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J Nucl Med. 2014;55(11):1856–63.
Mattila JT, et al. Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin alpha4beta1-expressing immune cells. J Immunol. 2017;199(2):806–15.
Peng L, et al. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol. 2006;2(7):381–9.
Kouroukis TC, et al. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014;21(4):e573-603.
San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.
Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.
Noborio-Hatano K, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28(2):231–42.
Sevilla-Movilla S, et al. Upregulated expression and function of the alpha4beta1 integrin in multiple myeloma cells resistant to bortezomib. J Pathol. 2020;252(1):29–40.
Wahl RL, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.
Mankoff DA, Katz SI. PET imaging for assessing tumor response to therapy. J Surg Oncol. 2018;118(2):362–73.
Fryer RA, et al. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS ONE. 2013;8(2):e57641.
Ishii T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012;2(4):e68.
Satou Y, et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004;18(8):1357–63.
Wang X, et al. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells. Anticancer Drugs. 2014;25(3):282–8.
Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005;5(1):18.
Savaikar MA, et al. Preclinical PERCIST and 25% of SUV(max) threshold: precision imaging of response to therapy in co-clinical (18)F-FDG PET imaging of triple-negative breast cancer patient-derived tumor xenografts. J Nucl Med. 2020;61(6):842–9.
Vanderheyden JL. The use of imaging in preclinical drug development. Q J Nucl Med Mol Imaging. 2009;53(4):374–81.
Ghai A, et al. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-Daratumumab for imaging multiple myeloma. J Nucl Med. 2018;59(2):216–22.
Pan Q, et al. Chemokine receptor-4 targeted PET/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020;47(3):537–46.
Ulaner GA, et al. CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology. 2020;295(3):606–15.
Hillengass J, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–12.
Anderson KC, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–93.
Durie BG, et al. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43(11):1457–63.
Matteucci F, et al. PET/CT in multiple myeloma: beyond FDG. Front Oncol. 2021. https://doi.org/10.3389/fonc.2020.622501.
Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.
Harzschel A, et al. VLA-4 expression and activation in B cell malignancies: functional and clinical aspects. Int J Mol Sci. 2020;21(6):2206.
Perkins LA, et al. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice. Blood Adv. 2020;4(17):4102–12.
Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26(4):308–14.
Baschnagel AM, et al. The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiother Oncol. 2015;117(1):118–24.
Ghai A, et al. Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. Eur J Nucl Med Mol Imaging. 2020;48:1302–11.
Hosen N. Integrins in multiple myeloma. Inflamm Regen. 2020;40:4.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.